A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
Status:
Completed
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
The primary objective of the phase 1 portion of this study is to determine the recommended
dose of bemarituzumab in combination with 5-fluorouracil, leucovorin and oxaliplatin
(modified FOLFOX6) to use in the phase 2 portion of the trial.